BLR-based Startup Cambrian Bioworks Bags $1.45 Mn in Seed Funding
The company’s products are pivotal in fields such as oncology, genomics, rare disease testing, and antimicrobial resistance (AMR) detection.
Bengaluru-based biotechnology startup Cambrian Bioworks has raised $1.45 million (INR 12 Cr) in a seed funding round led by the Irani family office, with participation from the company’s co-founder and CEO, Vaibhav Hegde.
The fresh capital will be used to scale up Cambrian's automated molecular diagnostics platforms, enhance research and development efforts, expand the team, and support international market expansion.
Founded in 2020 by Vaibhav Hegde, Rohit Asil, and Raghav Sridhar, Cambrian Bioworks specializes in building automated molecular diagnostic platforms.
The company’s products are pivotal in fields such as oncology, genomics, rare disease testing, and antimicrobial resistance (AMR) detection.
Cambrian's tools are designed to meet the needs of advanced DNA sequencing and molecular diagnostics markets.
"Molecular diagnostics is crucial for precise diagnosis, disease subtyping, and therapy selection in cancer care. This funding marks a significant milestone in our journey," said Hegde, highlighting the importance of the investment in the company’s growth.
In April, Cambrian Bioworks launched Manta, an automated platform for nucleic acid extraction.
This device efficiently extracts and purifies nucleic acids such as DNA, RNA, and cell-free DNA (cfDNA) from various clinical samples, marking a significant advancement in the company’s product lineup.
India's biotechnology sector, valued at over $92 billion in 2023, is on a rapid growth trajectory, with projections aiming for $150 billion by 2025 and $300 billion by 2030.
Cambrian Bioworks seeks to contribute significantly to this expansion, leveraging the rising demand for molecular diagnostics and biopharmaceutical innovations.
Recent Healthtech Fundings
Just days back, Even Healthcare, a Bengaluru-based subscription healthcare provider, secured INR 169 Cr ($20 million) in a new funding round led by Khosla Ventures.
This marks a significant boost after a 20-month funding gap. The startup issued 217,589 preference shares at INR 7,762 each, with Khosla Ventures contributing INR 83.4 Cr ($10 million).
Likewise, Bengaluru-based 4baseCare, a precision oncology solutions provider, successfully raised $6 million in Series A funding, led by Yali Capital along with other investors.
The startup, which leverages advanced genomics and digital health technology, aims to revolutionize cancer care through personalized treatment solutions.
